RT Journal Article
SR Electronic
T1 Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.15.22273915
DO 10.1101/2022.04.15.22273915
A1 Petrie, Joshua G.
A1 King, Jennifer P.
A1 McClure, David L.
A1 Rolfes, Melissa A.
A1 Meece, Jennifer K.
A1 Belongia, Edward A.
A1 McLean, Huong Q.
YR 2022
UL http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273915.abstract
AB During a period of Omicron variant circulation, we estimated relative VE of COVID-19 mRNA booster vaccination versus primary two-dose series in an ongoing community cohort. Relative VE was 66% (95% CI: 46%, 79%) favoring the booster dose compared to primary series vaccination. Our results support current booster recommendations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the US Centers for Disease Control and Prevention (Grant 75D30120C09259).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.